A strong launch, with little room for error
- MYQORZO is now on the market in the U.S. for obstructive hypertrophic cardiomyopathy, a heart muscle disease.
- The first partial quarter brought $4.8 million of net product revenue, ahead of management's internal expectations.
- Positive Phase 3 data in non-obstructive HCM could expand aficamten into a much larger patient group.
- A roughly $700 million May capital raise lowered near-term financing risk, but cash burn is still a major watch item.
- The stock depends heavily on one drug, so launch speed, access, patent litigation, and FDA reviews matter a lot.
Aficamten carries the story
Cytokinetics has crossed a big line. It is no longer only a drug developer. MYQORZO, also called aficamten, started U.S. commercial sales in January 2026 for symptomatic obstructive hypertrophic cardiomyopathy, or oHCM. In Q1 2026, the first partial quarter of launch, the drug produced $4.8 million of net product revenue.
The latest news made the bull case stronger. In May 2026, Cytokinetics reported positive top-line Phase 3 data from ACACIA-HCM in non-obstructive HCM, or nHCM. Management said aficamten improved symptoms and exercise capacity with no new safety signals. If regulators agree, MYQORZO could become the first therapy approved across the full HCM spectrum.
That creates a clear upside path: keep growing U.S. oHCM sales, file for nHCM, launch in Germany, and collect future value from partners in China and Japan. The pipeline also gives the company shots on goal beyond aficamten, including omecamtiv mecarbil and ulacamten.
The catch is price and execution. The stock is already being judged like MYQORZO will become a large product. Finn's view is more cautious because valuation and financial health are weak spots. If payors slow access, doctors stay with older choices, litigation cuts economics, or the nHCM filing disappoints, the story can break quickly.
A new drug launch funds the lab
Cytokinetics makes money mainly from MYQORZO product sales. For now, those sales are concentrated in the U.S. The first European launch is planned to begin in Germany, which should add a new market if reimbursement works.
The company also earns license, milestone, and collaboration revenue from partners. Sanofi controls aficamten rights in Greater China through its acquisition of Corxel's rights. Bayer is tied to Japan. In Q1 2026, Bayer-related license and milestone revenue was $11.9 million, and collaboration revenue was $2.6 million.
This is still an expensive business. Cytokinetics is funding a global commercial rollout, late-stage trials, and earlier research at the same time. It has also used royalty monetization, convertible notes, term loans, and a roughly $700 million capital raise to support the plan. Those tools buy time, but they do not remove the need for MYQORZO sales to scale.
One approved drug, several heart bets
MYQORZO® (aficamten) for oHCM
MYQORZO is an oral cardiac myosin inhibitor approved for symptomatic obstructive HCM. U.S. sales began in January 2026, making it the company's first commercial product.
Aficamten for nHCM
Positive Phase 3 ACACIA-HCM data opened the path to a supplemental FDA filing in non-obstructive HCM. Approval would widen the addressable market and could make aficamten the first approved therapy for the full HCM spectrum.
Omecamtiv mecarbil
Omecamtiv mecarbil is a cardiac myosin activator in development for heart failure with severely reduced ejection fraction. A new Phase 3 trial called COMET-HF is ongoing.
Ulacamten
Ulacamten is a next-generation cardiac myosin inhibitor being tested in heart failure with preserved ejection fraction. It is in the Phase 2 AMBER-HFpEF trial.
CK-089
CK-089 is a fast skeletal muscle troponin activator in Phase 1. It could be used in muscular dystrophy or other diseases where muscle function is impaired.
Q1 revenue is still early
Cytokinetics reports one operating segment, but Q1 2026 revenue can be viewed by source. The mix reflects the first partial quarter of MYQORZO sales, so milestone revenue made the quarter look less product-heavy than a mature launch would.
What can go wrong
MYQORZO launch stalls
High impact · Medium oddsCytokinetics depends heavily on MYQORZO becoming a large product. Early demand was better than management expected, but commercial insurance access is still being built. If payors add friction or doctors wait to switch patients, revenue growth could flatten.
FDA view on nHCM is less favorable
High impact · Medium oddsThe ACACIA-HCM top-line result is the biggest positive change in the thesis. The open question is how complete the full data look and how the FDA views the filing package. A slower review, request for more data, or narrow label would cut the market expansion case.
Patent litigation cuts economics
High impact · Medium oddsBMS and Myokardia are an important overhang because an unfavorable patent outcome could force royalties, a settlement, or other limits. That would matter more if MYQORZO becomes a large product. EU patent opposition proceedings are another legal watch item for Europe.
Cash burn stays high
High impact · High oddsThe roughly $700 million May raise gave Cytokinetics more time. Still, the company is funding sales teams, European infrastructure, and several clinical programs. If MYQORZO sales do not ramp fast enough, future financing could still dilute shareholders or add debt.
Single-source manufacturing fails
High impact · Low oddsCytokinetics relies on outside manufacturers and has no internal manufacturing capacity for MYQORZO. A supply problem with the active ingredient or finished tablets could interrupt launch momentum. This risk is common in biotech, but it is sharper when one product drives the story.
In one breath
What does Cytokinetics do?
Cytokinetics develops drugs that change how muscle proteins work. Its first approved product is MYQORZO for obstructive hypertrophic cardiomyopathy, a disease where the heart muscle becomes too thick and can block blood flow.
Why did the Cytokinetics thesis improve in 2026?
Two things changed. MYQORZO started selling in the U.S. and produced $4.8 million of net product revenue in its first partial quarter, while aficamten also posted positive Phase 3 data in non-obstructive HCM.
Is Cytokinetics profitable?
The company still has a history of major losses and high spending. The launch gives it a path to product revenue, but MYQORZO needs to ramp a lot before the business can support its research and commercial costs.
What are the next big dates for CYTK?
Investors are watching for the nHCM supplemental NDA submission, the Germany launch, and the November 14, 2026 PDUFA date for the MAPLE-HCM label update. Quarterly MYQORZO sales updates are also key.